Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Medical Genetics

Care Guidelines: Monitoring and Treatment Strategy

At a Glance

Tuberous sclerosis complex requires lifelong monitoring with brain, kidney, and lung scans, EEGs, blood tests, and regular exams. Results guide treatments such as everolimus or sirolimus, while sudden seizure, severe headache, bleeding, or breathing symptoms require emergency care.

Managing Tuberous Sclerosis Complex (TSC) requires a lifelong commitment to “surveillance”—the practice of using regular scans and exams to find and treat growths before they cause symptoms. Because the condition changes over a lifetime, your care team will use a standard schedule tailored to your age and symptoms to monitor your brain, kidneys, lungs, and other organs [1][2].

Your Surveillance Schedule

Current international guidelines recommend the following monitoring. Your doctor may adjust these intervals based on your specific needs [3].

  • Brain MRI: Every 1–3 years until age 25 to monitor for SEGA [1]. Adults may need continued scans if a SEGA is present [4].
  • EEG: Baseline at diagnosis. In seizure-free children, generally repeat approximately every 3 months through 24 months, and every 6 months to 48 months. Urgent/prolonged EEG is required if symptoms change [5].
  • Kidneys: Abdominal MRI (preferred over ultrasound) every 1–3 years to check for AML growth or cysts [6][2]. Annually: Blood pressure check, eGFR (kidney function blood test), and urinalysis for protein [7].
  • Lungs (Women): Baseline High-Resolution Chest CT at age 18 (or earlier if symptomatic). Follow-up depends on findings. Pulmonary function testing (PFTs) and VEGF-D blood tests are used to monitor for LAM [3][8].
  • Heart (Infants): Echocardiogram and ECG at diagnosis for rhabdomyomas and arrhythmias.
  • TAND Screening: Annual use of the TAND Checklist to monitor behavioral, psychiatric, and learning needs [3].
  • Eyes & Skin & Teeth: Annual clinical skin exams. Dilated eye exams (frequency depends on lesion stability). Routine dental care for enamel pits [3].

Targeted Therapy: mTOR Inhibitors

The most significant advancement in TSC care is the use of mTOR inhibitors like everolimus and sirolimus [9]. These medications are “targeted” because they inhibit the downstream mTOR signaling caused by the disabled TSC1/TSC2 mutations [10]. They do not repair the gene or cure the disease, and lesions may regrow if treatment stops.

When are they used?

  • Brain: To shrink SEGAs that are growing or cannot be safely removed by surgery [11].
  • Kidneys: For asymptomatic, actively growing AMLs larger than 3 cm [11][12].
  • Lungs: Sirolimus is the established treatment to stabilize lung function in women with clinically significant LAM [13].
  • Epilepsy: As an “add-on” treatment for seizures that do not respond to standard medications [14].

Side Effects and Monitoring

Because these drugs affect the immune system and metabolism, they require regular blood tests [15]. Common concerns include:

  • Stomatitis: Painful mouth sores are the most common side effect [9]. Doctors often recommend prescription dexamethasone mouth rinses as a preventive measure; avoid alcohol-based mouthwashes [16].
  • Infections & Warnings: You may be more prone to illnesses. Serious infections/fevers and noninfectious pneumonitis require immediate attention [15]. Avoid live vaccines unless advised by your team. Discuss pregnancy/contraception counseling.
  • Metabolic Changes: The drugs can raise cholesterol (dyslipidemia) or blood sugar levels [9].
  • Interactions: These medications interact with many substances, including CYP3A4-interacting drugs, grapefruit juice, and cannabidiol (CBD). Adding CBD can significantly increase the levels of everolimus in your blood, raising the risk of toxicity [17][18].

When to Seek Emergency Care

While routine monitoring is the rule, certain “red flag” symptoms mean you should go to the emergency room immediately.

1. Seizure Emergency (Status Epilepticus)

Call 911 if a seizure lasts 5 minutes or longer, if repeated seizures occur without recovery, if breathing is compromised, or for a first-ever seizure. Follow your written seizure rescue plan.

2. Brain Emergency (SEGA Complications)

If a SEGA grows large enough to block the flow of brain fluid, it causes hydrocephalus (increased pressure) [19].

  • Symptoms: Sudden, severe headache; projectile vomiting; new double vision or blurred vision; extreme sleepiness; or a sudden, dramatic increase in seizure frequency [19][20].

3. Kidney Emergency (AML Rupture)

Kidney tumors (AMLs) larger than 3 cm or those with aneurysms are at risk of bursting and causing internal bleeding [21].

  • Symptoms: Sudden, sharp, severe pain in your “flank” (the side of your back) or abdomen; blood in your urine; or feeling faint, dizzy, and pale (signs of shock) [21][22].

4. Lung Emergency (Pneumothorax)

In women with LAM, a lung cyst can pop, causing the lung to collapse (pneumothorax) [23].

  • Symptoms: Sudden, sharp chest pain on one side and shortness of breath that starts abruptly [23].

Note: Do not wait for your next scheduled scan if you experience any of these symptoms. These complications are treatable but require urgent medical intervention.

Common questions in this guide

How often should people with TSC have brain MRI scans?
Children with TSC are generally monitored with brain MRI every 1 to 3 years until age 25 to look for a TSC-related brain growth called a SEGA. Adults may need ongoing MRI scans if a SEGA is present, and the treating team may change the schedule based on symptoms and scan findings.
What kidney checks are recommended for TSC?
An abdominal MRI is usually done every 1 to 3 years to check for growing angiomyolipomas, also called AMLs, or kidney cysts. Blood pressure, kidney function, and urine protein should be checked every year.
When are everolimus or sirolimus used to treat TSC?
These targeted medicines may shrink a growing SEGA that cannot be safely removed, and everolimus may be used for an asymptomatic kidney AML that is actively growing and larger than 3 cm. Sirolimus can stabilize clinically significant LAM, a TSC-related lung condition, and an mTOR inhibitor may be added for seizures that do not respond to standard medicines. These medicines do not repair the gene or cure TSC.
What side effects and interactions should I watch for with TSC mTOR medicines?
Painful mouth sores are common, and these medicines can also increase infection risk or cause lung inflammation, high cholesterol, or high blood sugar. Regular blood tests are needed, and grapefruit, cannabidiol (CBD), and some other medicines can raise everolimus levels and increase toxicity risk.
When should I call emergency services for a seizure in TSC?
Call emergency services if a seizure lasts 5 minutes or longer, if seizures repeat without recovery, if breathing is affected, or if it is the person's first seizure. Follow the written seizure rescue plan if one is available.
Which symptoms could signal a brain emergency in TSC?
A sudden severe headache, forceful vomiting, new double or blurred vision, extreme sleepiness, or a sudden major increase in seizures can signal pressure from a growing SEGA. Do not wait for the next scheduled scan; seek emergency care immediately.
What symptoms suggest a kidney or lung emergency in TSC?
Sudden severe pain in the side or abdomen, blood in the urine, or faintness and pale skin may indicate bleeding from a ruptured kidney AML. In a woman with LAM, sudden one-sided chest pain and abrupt shortness of breath may indicate a collapsed lung; both situations need emergency evaluation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on our last MRI, when exactly is the next brain scan due, and is the current interval every 1, 2, or 3 years?
  2. 2.What is the exact schedule for EEG monitoring, kidney function tests, and blood pressure checks?
  3. 3.Does the 2021 consensus recommend a chest CT for me (or my child) yet to screen for LAM?
  4. 4.If we start an mTOR inhibitor, how often will we need blood tests to check my cholesterol, blood sugar, and drug levels?
  5. 5.What is our plan for managing potential infections or mouth sores if they develop while taking everolimus or sirolimus?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Subependymal Giant Cell Astrocytoma Size Measurement in Tuberous Sclerosis Complex: Noncontrast vs Contrast-Enhanced 3-Dimensional T1-Weighted Magnetic Resonance Imaging (MRI).

    Hill BJ, Gadde JA, Palasis S

    Journal of child neurology 2019; (34(14)):922-927 doi:10.1177/0883073819867541.

    PMID: 31424303
  2. 2

    Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas.

    Kingswood JC, Belousova E, Benedik MP, et al.

    Frontiers in neurology 2020; (11()):972 doi:10.3389/fneur.2020.00972.

    PMID: 33041968
  3. 3

    Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.

    Northrup H, Aronow ME, Bebin EM, et al.

    Pediatric neurology 2021; (123()):50-66 doi:10.1016/j.pediatrneurol.2021.07.011.

    PMID: 34399110
  4. 4

    Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study.

    Jansen AC, Belousova E, Benedik MP, et al.

    Frontiers in neurology 2019; (10()):821 doi:10.3389/fneur.2019.00821.

    PMID: 31428037
  5. 5

    Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations.

    Curatolo P, Nabbout R, Lagae L, et al.

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2018; (22(5)):738-748 doi:10.1016/j.ejpn.2018.05.006.

    PMID: 29880258
  6. 6

    Kidneys in Children with Tuberous Sclerosis Complex-An Up-to-Date Review.

    Wabik AM, Pytlos J, Michalczewska A, Skrzypczyk P

    Journal of clinical medicine 2025; (14(21)) doi:10.3390/jcm14217805.

    PMID: 41227201
  7. 7

    Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study.

    Janssens P, Van Hoeve K, De Waele L, et al.

    Pediatric nephrology (Berlin, Germany) 2018; (33(11)):2085-2093 doi:10.1007/s00467-018-4003-6.

    PMID: 29987458
  8. 8

    Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis.

    Hirose M, Matsumuro A, Arai T, et al.

    PloS one 2019; (14(2)):e0212776 doi:10.1371/journal.pone.0212776.

    PMID: 30818375
  9. 9

    Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide.

    Davies M, Saxena A, Kingswood JC

    Orphanet journal of rare diseases 2017; (12(1)):35 doi:10.1186/s13023-017-0581-9.

    PMID: 28202028
  10. 10

    The Neurodevelopmental Pathogenesis of Tuberous Sclerosis Complex (TSC).

    Feliciano DM

    Frontiers in neuroanatomy 2020; (14()):39 doi:10.3389/fnana.2020.00039.

    PMID: 32765227
  11. 11

    Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.

    Samuels JA

    Clinical journal of the American Society of Nephrology : CJASN 2017; (12(7)):1196-1202 doi:10.2215/CJN.08150816.

    PMID: 28302901
  12. 12

    Recommendations for imaging-based diagnosis and management of renal angiomyolipoma associated with tuberous sclerosis complex.

    Buj Pradilla MJ, Martí Ballesté T, Torra R, Villacampa Aubá F

    Clinical kidney journal 2017; (10(6)):728-737 doi:10.1093/ckj/sfx094.

    PMID: 29225800
  13. 13

    Lymphangioleiomyomatosis in patients with tuberous sclerosis: a national centre audit.

    Johnson J, Somerfield W, Johnson SR

    Orphanet journal of rare diseases 2024; (19(1)):137 doi:10.1186/s13023-024-03115-y.

    PMID: 38532450
  14. 14

    Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.

    Moavero R, Mühlebner A, Luinenburg MJ, et al.

    Epilepsy & behavior : E&B 2022; (131(Pt B)):107713 doi:10.1016/j.yebeh.2020.107713.

    PMID: 33431351
  15. 15

    Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening.

    Trelinska J, Dachowska I, Kotulska K, et al.

    Anti-cancer drugs 2015; (26(4)):437-42 doi:10.1097/CAD.0000000000000207.

    PMID: 25719621
  16. 16

    Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.

    Saffari A, Brösse I, Wiemer-Kruel A, et al.

    Orphanet journal of rare diseases 2019; (14(1)):96 doi:10.1186/s13023-019-1077-6.

    PMID: 31053163
  17. 17

    Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex.

    Ebrahimi-Fakhari D, Agricola KD, Tudor C, et al.

    Pediatric neurology 2020; (105()):59-61 doi:10.1016/j.pediatrneurol.2019.11.017.

    PMID: 31924480
  18. 18

    Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway.

    Kirkeby K, Cockerell I, Christensen J, et al.

    Medicine 2024; (103(32)):e39244 doi:10.1097/MD.0000000000039244.

    PMID: 39121325
  19. 19

    Subependymal Giant Cell Astrocytoma Without Clinical Evidence of Tuberous Sclerosis Complex: Diagnostic and Molecular Insights-Case Report.

    Pickler JGJ, Fronza Junior H, Pedack FR, et al.

    Neurology international 2026; (18(7)) doi:10.3390/neurolint18070135.

    PMID: 42506057
  20. 20

    Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex.

    Jansen AC, Belousova E, Benedik MP, et al.

    Frontiers in neurology 2019; (10()):705 doi:10.3389/fneur.2019.00705.

    PMID: 31333563
  21. 21

    Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.

    Brakemeier S, Bachmann F, Budde K

    Pediatric nephrology (Berlin, Germany) 2017; (32(7)):1137-1144 doi:10.1007/s00467-016-3474-6.

    PMID: 27585680
  22. 22

    Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness.

    Kingswood JC, Belousova E, Benedik MP, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2019; (34(3)):502-508 doi:10.1093/ndt/gfy063.

    PMID: 29697822
  23. 23

    Tuberous Sclerosis Complex: State-of-the-Art Review with a Focus on Pulmonary Involvement.

    von Ranke FM, Zanetti G, e Silva JL, et al.

    Lung 2015; (193(5)):619-27 doi:10.1007/s00408-015-9750-6.

    PMID: 26104489

This page explains TSC monitoring and treatment for informational purposes only and does not constitute medical advice. Your TSC team should personalize scan schedules, medicines, and emergency plans for you or your child.

Get notified when new evidence is published on Tuberous sclerosis complex.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.